Leadership

March 30, 2026 Alnylam Named One of Fast Company's Most Innovative Companies for 2026 RNAi therapeutics pioneer has been recognized by Fast Company as one of the most innovative companies for the 3rd time and ranks #3 in the "Medicines and Therapeutics" category. Read More ›
March 26, 2026 Alnylam Awarded 2026 Scientific Impact Award by MassBio Alnylam was recognized by Mass Bio for its pioneering work in RNA interference and the development of RNAi therapeutics as an innovative new class of medicines. Read More ›
February 12, 2026 Alnylam BioVenture Challenge: Supporting the Next Generation of Biotech Leaders The Alnylam BioVenture Challenge is a partnership with Nucleate designed to empower the next generation of biotech leaders. Discover how we're supporting bold scientific ideas to advance the future of medicine. Read More ›
March 29, 2023 Leading by Example in Gender Diversity Among Executive Leadership Alnylam ranked #1 among MA public companies in board of directors gender diversity and #3 in executive leadership gender diversity in the 2023 WPG report.   Read More ›
March 2, 2023 Alnylam Named One of Fast Company's Most Innovative Companies for 2023 Alnylam is one of Fast Company's Most Innovative Companies for 2023, and is ranked #5 in the Medicines and Therapeutics category. Read More ›
July 13, 2022 Partnering with Nucleate to Support Young Biotech Entrepreneurs Alnylam is partnering with Nucleate to remove barriers for young biotech entrepreneurs... Read More ›
October 28, 2021 Alnylam Names Dr. Yvonne Greenstreet New CEO Dr. Yvonne Greenstreet, currently Alnylam's President and COO, has been named Alnylam's new CEO effective year-end 2021, taking over from Dr. John Maraganore. Read More ›
April 26, 2021 Diversity Equity & Inclusion at Alnylam: Building on the Momentum to Create Lasting Impact ... Sara Nochur, Alnylam's Chief Diversity, Equity & Inclusion Officer talks about DE&I at Alnylam and her role leading the company's efforts. Read More ›
December 7, 2020 Alnylam Publishes Its 1st-Ever Rare Disease Trend Report Alnylam's 2020 Rare Disease Trend Report features findings from interviews with 30 U.S. payer and plan decision-makers about barriers to orphan drug access. Read More ›
August 6, 2020 Alnylam Promotes Dr. Yvonne Greenstreet to President & COO Dr. Yvonne Greenstreet, has been elevated to the role of President of Alnylam. She will retain her COO role as well. Read More ›
Subscribe to Leadership